OTC Monograph or NDA: Which Path Fits Your Oral Care Product
This article is meant for inventors, formulators and manufacturers more than everyday consumers. It covers how monograph actually gets tested, the spots where oral care products tend to slip outside the monograph without anyone catching it and what the application route looks like when the product doesn’t fit. It also gets into the third option most people overlook, which is asking FDA to change the monograph itself through an order request. Earlier posts here on toothpaste claims that trigger clinical trials and mouthwash ingredients that trigger NDA requirements came at this problem from the ingredient side, so this one stays focused on the decision framework.

Why the OTC Monograph or NDA Question Starts With Four Conditions
The legal structure behind all of this is the definition of a "new drug" in 21 U.S.C. 321(p), which says a drug is new unless it is generally recognized, among scientists qualified by training and experience, as safe and effective for use under the conditions prescribed, recommended or suggested in its labeling. That last clause carries the entire analysis, because general recognition is never a property of a molecule sitting in a drum. Sodium fluoride is not GRASE in the abstract, and neither is potassium nitrate or hydrogen peroxide. An ingredient is GRASE, or it is not, for a stated concentration in a stated dosage form for a stated indication with stated labeling, and changing any one of those means the question has to be asked again from the beginning.
A monograph is the document where FDA answers that question for a whole category at once instead of product by product, and since the CARES Act added section 505G to the FD&C Act in March 2020, each monograph takes the form of an administrative order rather than a regulation in the Code of Federal Regulations. The practical rule is unchanged from the old system, because a product that meets every condition in the order, plus the general conditions in 21 C.F.R. 330.1 and the Drug Facts labeling format in 21 C.F.R. 201.66, is deemed not to require an approved application under section 355. A product that misses any condition is a new drug, and 21 U.S.C. 355(a) prohibits introducing a new drug into interstate commerce without an approved application.
So the fit test has four parts that get checked in order, and a miss on any one of them ends the inquiry. The first is the active ingredient itself, meaning whether the monograph names it at all. The second is concentration, because monographs set exact percentages or ranges, and a formula that lands outside the range is outside the monograph even if the ingredient is listed. The third is dosage form, since a monograph that recognizes a dentifrice and a rinse does not automatically recognize a strip, a pen, a chewing gum, a lozenge or a tray gel. The fourth is the indication and the labeling that carries it, which is where marketing teams cause the most trouble, because a claim that goes one step past the monograph's permitted language turns a monograph product into an unapproved new drug without changing a single ingredient.
What the Monograph Route Gives You and What It Takes Away
The appeal of the monograph route is easy to state, because a company that stays inside the order owns its own timeline and answers to FDA only if something goes wrong. There is no premarket submission, no review clock and no user fee on the application side, although the facility still has to register and list and still pays the annual OMUFA facility fee if it manufactures monograph drugs. Reformulation within the monograph's ranges needs no permission, a label change that stays within the permitted claims needs no permission and a launch date is a business decision rather than a regulatory one.
What the route takes away is flexibility on everything the panel and the agency did not anticipate when the conditions were written, and in oral care the conditions were largely written decades ago on the dosage forms and the science of that era. The anticaries order, now designated OTC Monograph M021, recognizes specific fluoride compounds at specific concentrations in dentifrices and rinses, and it carries labeling that must be reproduced closely. The oral health care order, OTC Monograph M022, covers products such as oral debriding agents and oral mucosal analgesics with their own narrow ingredient lists. The tooth desensitizer conditions that reached tentative final monograph status in 1991 were carried forward under the CARES Act's deemed final provisions, which is why potassium nitrate toothpaste for sensitivity can be sold without an application. Each of those sets of conditions is a box with hard edges, and the edges do not move to accommodate a better idea.
A company that wants to market a monograph product also inherits the monograph's labeling as a near verbatim script, which surprises founders who expected to write their own Drug Facts panel. The required indication language, warnings and directions have to appear as the order states them, and the front panel claims and marketing copy have to stay consistent with that panel. A fluoride toothpaste can say it helps prevent cavities because the order lets it say so, and it cannot say it rebuilds enamel or reverses decay unless that claim can be tied back to the same permitted language, because an unpermitted claim is a new indication and a new indication is a new drug.
Where Oral Care Products Fall Out of the Monograph Without Anyone Noticing
The most often failures are not the dramatic ones where a company tries to sell a brand new molecule, because those companies usually know they are in new drug territory from the start. The common failure is a product that is monograph compliant on three of the four conditions and off on the fourth, and the miss is nearly always in a direction nobody was watching while attention was somewhere else.
Dosage form is the quiet one, since a founder who has read that stannous fluoride is a recognized anticaries ingredient will sometimes assume that recognition travels with the ingredient into a whitening strip, a dissolvable tablet, a foam or a mouth spray. The anticaries order recognizes the ingredient in a dentifrice and in a rinse at defined concentrations, and a tablet that you chew into a paste is a different dosage form with a different exposure profile, which means the general recognition finding does not reach it. The same problem shows up with combination products, because the general combination rule in the OTC regulations requires each active to contribute to the claimed effect and the combination to be rational therapy, and a monograph that recognizes two ingredients separately does not necessarily recognize them together in one product.
Concentration is the second quiet failure, and it cuts in both directions in ways that catch careful people. A formulator who pushes the fluoride level up to chase a stronger claim leaves the order's range at the top, and a formulator who dilutes it to save cost or to hit a kids' product target can leave it at the bottom, where the product no longer qualifies for the anticaries indication at all. Pediatric fluoride products carry their own concentration and labeling rules inside the order, and a product that mixes adult and pediatric conditions, for example an adult concentration with a kids' flavor and a kids' front panel, raises a labeling adequacy question the order was not written to answer.
Indication is the loud one, and the one that pulls the FTC in alongside FDA. Whitening is the clearest example, because there is no OTC monograph for tooth whitening and peroxide whiteners have historically been handled outside the drug monograph system, so a whitening product that also carries a fluoride anticaries claim is straddling two regulatory statuses in one package. Antiplaque and antigingivitis claims are another, since that category never reached a final rule and the agency's position on which ingredients and claims are supported has been covered in earlier posts here. A rinse that calls itself an anticaries fluoride rinse under the order and then adds "fights gum disease" on the front panel has made a claim the order does not support, and FDA reads the front panel the same way the consumer does.
Labeling format is the last and most mechanical failure, because the Drug Facts regulation at 21 C.F.R. 201.66 dictates headings, order, type size and content, and a product that carries the right ingredient at the right concentration in the right form with the right indication can still be misbranded if the panel is laid out wrong. That failure is usually fixable with a label revision rather than an application, but it still reaches a warning letter when it is combined with claims problems.
The NDA Route, Including the 505(b)(2) Application
When the fit is not there and the company does not want to change the product to create it, the route is an application under section 505 of the FD&C Act, and for an oral care product that usually means one of two things. A full application under 505(b)(1) rests entirely on studies the applicant conducted or has a right of reference to, and it is the route for a new active ingredient or a product where no prior finding of safety or effectiveness can be borrowed. A 505(b)(2) application allows the applicant to rely in part on published literature and on FDA's prior findings for a listed drug, which fits a product that uses a known ingredient in a new dosage form, a new concentration or a new indication, which is exactly the shape of most oral care products that fall out of the monograph.
The cost side is where founders tend to underestimate the decision, and it is worth being plain about it. An NDA carries a PDUFA application fee that is published each year in the Federal Register and that has run above four million dollars in recent fiscal years for an application with clinical data, plus annual program fees once the product is approved, and that is before the cost of the clinical work. Effectiveness for an OTC indication still has to be shown through adequate and well controlled investigations, and for a cavity prevention claim that has historically meant multi year caries clinical trials in defined populations, which is a materially heavier lift than the plaque and gingivitis endpoints that run in months.
What the application buys in return is worth stating just as plainly, because an approved NDA is product specific and belongs to the applicant. The approval covers the exact formulation, dosage form and labeling in the application, the labeling can carry claims the monograph would never permit as long as the data support them and the applicant may have market exclusivity for a period depending on the type of studies submitted. That difference is the entire commercial logic for companies that take the application route on purpose rather than by accident.
The Third Door Is an OTC Monograph Order Request
The CARES Act created a route that sits between the two, and it gets less attention than it deserves because it did not exist for most of the industry's history. Section 505G lets any requestor ask FDA to issue an administrative order that adds, changes or removes a monograph condition, and the request is called an OTC monograph order request, or OMOR. The earlier post on this blog from August 2026 walks through the mechanics, so the short version here is that a company that wants a new dosage form, a new concentration or a new indication added to an existing oral care monograph can ask for it directly, with supporting data, instead of filing an application for one product.
The fee structure tells you what Congress had in mind, because the fiscal year 2026 rates set the Tier 1 fee for a substantive change such as a new ingredient or a new indication at $587,529 and the Tier 2 fee for a minor change such as a label reordering at $117,505, both in effect through September 30, 2026. Those are large numbers for a startup and small numbers next to an NDA, and the trade is that a successful order request changes the monograph for everyone, including every competitor, while an approved application belongs to the applicant alone. A company with a defensible formulation advantage and a desire to own the market tends toward the application, while a company that wants the category opened up and is content to compete inside it tends toward the order request.
Two developments from this year matter for anyone weighing that door, and both are easy to miss. On July 16, 2026, FDA published a notice at 91 Fed. Reg. 43647 describing the process it will use to issue Data Requests, which are calls for public data to inform FDA initiated proposed orders such as adding a GRASE condition to a monograph, and the agency plans to list upcoming requests in its annual forecast of planned monograph activities. A company sitting on data that supports a new oral care condition should watch that portal, because supplying data in response to an agency initiated request can be a far cheaper way to move a condition into a monograph than paying the Tier 1 fee to initiate the request yourself. The second is simply the fee cycle, since the fiscal year 2027 rates will be published in the Federal Register and anyone budgeting an order request should check the current notice rather than last year's number.
A Working Method for Deciding Between the Paths
The method that works in practice starts with the label rather than the formula, because the indication the company intends to put on the front panel is the condition most likely to fail and the one marketing is least willing to give up. Write out every claim the product will make, including the ones that will live on the website and in the social media copy, and then find the monograph language that supports each one. A claim with no supporting monograph language is either coming off the product or it is pushing the product toward an application, and the company should make that choice with its eyes open rather than discovering it in a warning letter.
Next comes the dosage form and concentration check against the current order, and here the discipline is to read the order itself rather than a summary of it, because the designations changed when the monographs were converted into administrative orders and the current text lives on the OTC Monographs at FDA portal rather than in the old Code of Federal Regulations parts. Confirm that the exact form is named, confirm that the concentration sits inside the stated range for that form and confirm that any pediatric conditions are met if the product will be marketed to or used by children. A product that passes those checks and makes only permitted claims can be built around the monograph, and the remaining work is labeling format, registration and listing, good manufacturing practice and the OMUFA facility fee.
A product that fails one of those checks has three honest options, and the choice among them is a business decision informed by legal and scientific constraints rather than a legal decision alone. The company can change the product or the claim to bring it inside the order, which is the fastest and cheapest path and the one most startups should take for a first product. The company can file an application, most often under 505(b)(2), which costs the most and takes the longest and delivers a product specific approval the competition cannot borrow. Or the company can pursue an order request, alone or with an industry group, which costs less than an application, takes a timeline that is still being established in practice and opens the category for everyone if it succeeds. The wrong answer is the fourth option that too many products take by default, which is marketing outside the monograph while assuming that enforcement discretion is the same thing as permission, because it is not, and the recall and warning letter history in this category shows what happens when that assumption fails.
Howard Law focuses on FDA and FTC regulatory work for oral care products alongside its corporate and M&A practice, and the Regulatory Law page on this site describes how the firm approaches monograph fit reviews, label reviews and pathway decisions for new products. If you are at the fork described in this post, call or text 980-272-7322 and we can walk through where your product actually sits.
This post is general information about the law and the regulatory process for oral care products and nothing more. It is not legal advice, it does not address any particular product or set of facts and reading it does not create an attorney-client relationship with Howard Law or any of its attorneys.




Comments